VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval
The Vaccine and Infectious Disease Organization at the University of Saskatchewan has received a notice of authorization from Health Canada to initiate a Phase 1 clinical vaccine trial.
VIDO-InterVac on track to become ‘Canada’s centre for pandemic research’
A major takeaway from the COVID-19 pandemic is that emerging diseases require rapid responses and Canada needs to be better prepared to respond to the next one, says University of Saskatchewan research centre leader Dr. Volker Gerdts.
New CT scanner gives USask’s VIDO-InterVac scientists a window on COVID-19 disease
New imaging equipment to help understand COVID-19 infection will soon be coming to the VIDO-InterVac at the USask, thanks to a Canada Foundation for Innovation grant announced today by Prime Minister Justin Trudeau.
Extending the lifespan of N95 masks
Researchers at the CLS and VIDO-InterVac are working together to better understand how decontamination procedures might affect the structure and potential reuse of N95 masks.
USask VIDO-InterVac expands international role to test antiviral compounds against COVID-19
VIDO-InterVac at the University of Saskatchewan has been awarded a grant of almost $830,000 from the COVID-19 Therapeutics Accelerator to determine the effectiveness of several antiviral compounds against COVID-19.
Canadian universities partner to fight COVID-19 at USask’s VIDO-InterVac
Infectious disease experts from Dalhousie University and University of Manitoba are joining the leading-edge research team at VIDO-InterVac on one-year secondments to collaboratively advance research and development against COVID-19.
CFI awards $77.5M to help major USask science facilities address COVID-19 and other global challenges
Funding through the Canada Foundation for Innovation’s (CFI) Major Science Initiatives Fund ensures Canada’s large, national research facilities have the support needed to operate and stay on the leading edge of research.
Salmonella biofilm protein causes autoimmune responses—possible link with Alzheimer’s, Parkinson’s
Scientists from VIDO-InterVac and Temple University in Philadelphia, Penn., have demonstrated that a salmonella biofilm protein can cause autoimmune responses and arthritis in animals.
Promising pre-clinical results for USask VIDO-InterVac COVID-19 vaccine
A COVID-19 vaccine candidate developed by VIDO-InterVac has cleared another major milestone in moving towards human clinical trials: the novel vaccine has proven highly effective in ferrets, one of the commonly used animal models for COVID-19.
USask’s VIDO-InterVac and the National Research Council of Canada collaborate to advance development of vaccine against COVID-19
VIDO-InterVac and NRC announced a collaboration to accelerate the development and production of a candidate COVID-19 antigen in mammalian cells.